Zobrazeno 1 - 10 of 18 pro vyhledávání: '"R C Inhorn"'
1
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region
Autor: M Eder, Bruce A. Witthuhn, N Sato, James N. Ihle, Frederick W. Quelle, Atsushi Miyajima, James D. Griffin, R C Inhorn
Publikováno v: Molecular and Cellular Biology. 14:4335-4341
The high-affinity receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) consists of a unique alpha chain and a beta c subunit that is shared with the receptors for interleukin-3 (IL-3) and IL-5. Two regions of the beta c chain have b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c558d456d0e90cefaa55c4ff2f3543a9
https://doi.org/10.1128/mcb.14.7.4335
Zobrazit plný text záznamu
2
Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines
Autor: M, Durstin, R C, Inhorn, J D, Griffin
Publikováno v: Journal of immunology (Baltimore, Md. : 1950). 157(2)
The receptor for human granulocyte-macrophage (GM)-CSF (GMR) is a heterodimer, consisting of an alpha-chain (GMR alpha) and a beta-chain (GMR beta). While GMR alpha is capable of binding GM-CSF, GMR beta is necessary for signal transduction. Phosphor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dd52b2e93fbb4bc50b6dad370441635b
https://pubmed.ncbi.nlm.nih.gov/8752899
Zobrazit plný text záznamu
3
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity
Autor: R C, Inhorn, J C, Aster, S A, Roach, C A, Slapak, R, Soiffer, R, Tantravahi, R M, Stone
Publikováno v: Blood. 85(7)
We report two patients with a distinctive biphenotypic hematologic disorder characterized by lymphoblastic lymphoma (LBL), eosinophilia, and myeloid malignancy and/or hyperplasia associated with a t(8;13)(p11;q11) chromosomal translocation in both bo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4d9ff65c1e14818bc4825468f8889220
https://pubmed.ncbi.nlm.nih.gov/7606017
Zobrazit plný text záznamu
4
SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC)
Autor: K. Motamed, Hope S. Rugo, Neil P. Desai, D. A. Yardley, Brooke R. Daniel, E. Vazquez, Vuong Trieu, Larn Hwang, R. C. Inhorn
Publikováno v: Journal of Clinical Oncology. 28:10574-10574
10574 Background: SPARC, an albumin-binding protein, may mediate intratumoral accumulation of nab-P and is associated with poor prognosis in many tumors. In tumor microenvironments (M), SPARC is associated with tumor and stromal components. Previous
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07d5b08756d5562ebd6fe69a4e616095
https://doi.org/10.1200/jco.2010.28.15_suppl.10574
Zobrazit plný text záznamu
5
Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts)
Autor: L. Franco, D. A. Yardley, M. Lange, N. W. Peacock, E. Vazquez, John D. Hainsworth, Mythili Shastry, E. Raefsky, R. C. Inhorn, Victor M. Priego
Publikováno v: Journal of Clinical Oncology. 27:e11509-e11509
e11509 Background: Docetaxel/cyclophosphamide has demonstrated superior disease free and overall survival compared to doxorubicin/cyclophosphamide in the treatment of early stage breast cancer with an acceptable safety profile, with grade (G) 3/4 neu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::101283c05d3559c7a665c9d9a9f45b90
https://doi.org/10.1200/jco.2009.27.15_suppl.e11509
Zobrazit plný text záznamu
6
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
Autor: John D. Zubkus, Brooke R. Daniel, D. Knauer, Y. Naot, R. C. Inhorn, Cassie M. Lane, D. A. Yardley, Vuong Trieu, Davey B. Daniel, Neil P. Desai
Publikováno v: Journal of Clinical Oncology. 27:618-618
618 Background: Neoadjuvant combinations of gemcitabine (G), anthracyclines and taxanes have demonstrated substantial activity with pCR rates of 20–25%. Secreted protein acidic rich in cysteine (SPARC) is an albumin binding protein that mediates in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29af4a50b85eaf07b51aaa1be00be08b
https://doi.org/10.1200/jco.2009.27.15_suppl.618
Zobrazit plný text záznamu
7
Preliminary progression free survival and SPARC tumor correlatives from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel
Autor: N. Desai, V Trieu, S. Hanson, Brooke R. Daniel, H. A. Burris, Denise A. Yardley, Davey B. Daniel, J. Zubkus, Y. Naot, D. Knauer, R. C. Inhorn
Publikováno v: Cancer Research. 69:5116
Abstract #5116 Background: Neoadjuvant combinations of gemcitabine (G), anthracyclines and taxanes have demonstrated significant activity with pCR rates of 20-25% albeit with significant myelosuppression. Secreted protein acidic rich in cysteine (SPA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcead37b91a4d36a27225539d33bab60
https://doi.org/10.1158/0008-5472.sabcs-5116
Zobrazit plný text záznamu
8
Phase II study of neoadjuvant gemcitabine, epirubicin, and albumin-bound nab paclitaxel (GEA) in locally advanced breast cancer with SPARC tumor assessments
Autor: Davey B. Daniel, Vuong Trieu, D. Knauer, R. C. Inhorn, L. Simons, Neil P. Desai, D. A. Yardley, Brooke R. Daniel, Y. Naot, John D. Zubkus
Publikováno v: Journal of Clinical Oncology. 26:603-603
603 Background: Gemcitabine (G), anthracyclines and taxanes have significant activity as neoadjuvant therapy. SPARC, a known prognostic factor for poor survival, is an albumin binding protein that may mediate intratumoral accumulation of nab-paclitax
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c3048dfed9fb196909ae4dae70f41a9
https://doi.org/10.1200/jco.2008.26.15_suppl.603
Zobrazit plný text záznamu
9
Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
Autor: David R. Spigel, R. C. Inhorn, J. R. Infante, E. Vazquez, John D. Hainsworth, Charles D. Webb, H. A. Burris, J. R. Rubinsak, D. A. Yardley, F. A. Greco
Publikováno v: Journal of Clinical Oncology. 26:19045-19045
19045 Background: Disrupting epidermal growth factor receptor signaling is an effective treatment strategy in NSCLC. Cetuximab targets this receptor and is a standard treatment in colon and head an...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::153d578f0c6528f56fd58e3072d923f5
https://doi.org/10.1200/jco.2008.26.15_suppl.19045
Zobrazit plný text záznamu
10
Metabolites of all-trans-retinoic acid in bile: identification of all-trans- and 13-cis-retinoyl glucuronides
Autor: M H Zile, H. F. DeLuca, R C Inhorn
Publikováno v: Journal of Biological Chemistry. 257:3537-3543
The metabolites of all-trans-[3H]retinoic acid were studied in the rat bile. In the bile duct cannulated rat 80 to 86% of the dose is excreted into the bile within 24 h after the intravenous administration of either a physiological or pharmacological
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7c6dca442969a5195b4598e938ba462
https://doi.org/10.1016/s0021-9258(18)34812-9
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje